Navigation Links
Gentech Pharmaceutical Appoints New Medical Director for PhenTabz/ADDTabz
Date:5/22/2012

FORT MYERS, Fla., May 22, 2012 /PRNewswire-iReach/ -- Gentech Pharmaceutical announced today that Dr. Stan Headley has joined the company as Medical Director for its' PhenTabz and ADDTabz products. Dr. Headley brings over 15 years of experience to the world of Integrative Medicine. He holds a Doctorate of Medicine from Spartan Health Science University with clinical training in family medicine at Creighton University School of Medicine and St. Joseph's Hospital in Omaha, Nebraska.

Dr. Headley has served in various capacities in Natural Health as a clinical family medicine practitioner, Chief Medical Officer, Medical Director, Clinical Operations Manager, Natural Products Researcher, Product Training Educator and advocate as a guest speaker on various radio and television programs on Natural Health forums including International radio programs in Puerto Rico and Barbados.

"Dr. Headley's wealth of experience and industry knowledge has already made him a key addition to the Gentech Pharmaceutical family. We are extremely excited to have him as our Medical Director as we continue to grow. Our current products PhenTabz and ADDtabz and new innovations currently in development, paired with increasing demand from our customers led us to look for a skilled professional who understood the incredible opportunities in the field of designer pharmacological alternatives. We have found that professional in Dr. Stan Headley.", says Derek Vest, CEO.

About Gentech Pharmaceutical
Gentech Pharmaceutical applies the science of perfecting and improving current medications and OTC formulations/chemical structures to produce "designer pharmacological alternatives" without the side effects. This unique ability allows Gentech Pharmaceutical to produce the most therapeutically advanced and safe pharmacological products currently available. Gentech shares the most basic and sacred goals of the physicians whom they provide products to: improve the health and well-being of patients with the safest and most effective products available in PhenTabz and ADDTabz.

Press release submitted by SubmitPressRelease123.com

Media Contact: Mike Sharp Gentech Pharmaceutical, 888-666-1714, marketing@gentechpharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Gentech Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Golden Globe Awards Adds Gentech Pharmaceutical as New Participating Sponsor
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
Breaking Medicine News(10 mins):